Breaking News, Financial News

Financial Report: Ligand

Revenues up 56% in the quarter driven by Captisol

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand 4Q Revenues: $23.0 million (+56%) 4Q Earnings: $7.1 million (+278%) FY Revenues: $64.5 million (+32%) FY Earnings: $12.0 million (+5%) Comments: Royalty revenues increased 32% in the quarter to $9.4 million primarily due to higher royalties from Promaca and Kyprolis. Material sales increased to $13.0 million from $6.8 million in 4Q13 due to higher demand for Captisol for both clinical and commercial uses....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters